1-11 of 11
Douglas E Joshua, MBBS DPhil
Close
Sort by
Journal Articles

Protective Cytotoxic Clonal T-Cells in Myeloma Have the Characteristics of Telomere-Independent Senescence Rather Than an Exhausted or Anergic Phenotype: Implications for Immunotherapy

Hayley Suen, BSc (Hons), Douglas E Joshua, MBBS DPhil, Ross D Brown, PhD, Shihong Yang, MSc, Pasquale Mario Barbaro, MBBS, P Joy Ho, MBBS DPhil, John Gibson, MBBS PhD
Journal: Blood
Blood (2014) 124 (21): 3367.
https://doi.org/10.1182/blood.V124.21.3367.3367
Published: 2014
Journal Articles

Ten Year Survival in Patients with Myeloma Is Characterized by the Persistence of Immunological Control Which Is Detected by Immunological Biomarkers

Ross D Brown, PhD, Hayley Suen, BSc (Hons), Christian E Bryant, MBBS, Shihong Yang, MSc, James Favaloro, BSc, John Gibson, MBBS PhD, P Joy Ho, MBBS, DPhil, Phillip Fromm, PhD, Derek NJ Hart, MBCHB, DPhil, Douglas E Joshua, MBBS, DPhil
Journal: Blood
Blood (2012) 120 (21): 1818.
https://doi.org/10.1182/blood.V120.21.1818.1818
Published: 2012
Journal Articles

Blockade of the Hedgehog Signaling Pathway by the Novel Agent NVP-LDE225 Induces Differentiation, Prevents De-Differentiation and Inhibits Proliferation of Multiple Myeloma Stem Cells in Vitro

Shihong Yang, MSc, Ross D Brown, PhD, Yen S Loh, PhD, Hayley Suen, BSc (Hons), James Favaloro, BSc, John Gibson, MBBS, PhD, Phoebe Joy Ho, MBBS, DPhil, Douglas E Joshua, MBBS, DPhil
Journal: Blood
Blood (2012) 120 (21): 3950.
https://doi.org/10.1182/blood.V120.21.3950.3950
Published: 2012
Journal Articles

Bortezomib-Based Induction Overcomes Effect of 1q Amplification On Response in Newly-Diagnosed Myeloma and Results in Similar 2 Year Event-Free Survival

Douglas E Joshua, MBBS, DPhil, Mark S Hertzberg, MD, PhD, Bradley Auguston, Andrew Spencer, MD, Noemi Horvath, MB, ChB, FRACP, FRCPA, John Bashford, MBBS, FRACP, FRCPA, Lynda J Campbell, Eleanor Ashurst, Jacquelyn Wade, Michael C. Copeman, DPhil, FRACP, Belinda E Butcher, BSc(Hons) MBiostat PhD, Miles Prince, MD, FRACP, FRCPA
Journal: Blood
Blood (2012) 120 (21): 4065.
https://doi.org/10.1182/blood.V120.21.4065.4065
Published: 2012
Journal Articles

Lower Drug Exposure Is Related to Renal Function and Results in Inferior Survival: A Pharmacokinetic Study of High Dose Melphalan in Myeloma

Judith Trotman, MBChB, Peter J. Shaw, MBBS, MA, Douglas E Joshua, MBBS, DPhil, Yiu-Lam Kwan, MBBS, Campbell Tiley, MBBS, FRACP, FRCPA, Peter Presgrave, MBBS, PhD, Ian H. Kerridge, MBBS, MPhil, Christa Nath, BSc (Hons), PhD
Journal: Blood
Blood (2012) 120 (21): 1979.
https://doi.org/10.1182/blood.V120.21.1979.1979
Published: 2012
Journal Articles

Safety and Efficacy of CEEP (Cyclophosphamide, Epirubicin, Etoposide, Prednisolone) with or without Rituximab in Elderly Patients (>70) with Diffuse Large B-Cell Lymphoma (DLBL): A Retrospective Single Center Experience

Danny Hsu, MBBS FRACP FRCPA, Ibrahim Tohidi-Esfahani, MBBS, Christina Brown, MBBS PhD FRACP FRCPA, Scott Dunkley, MBBS FRACP FRCPA, Stephen Robert Larsen, MBBS FRACP FRCPA PhD, Phoebe Joy Ho, MBBS FRCPA FRACP DPhil, Harry Iland, MBBS FRACP FRCPA MHGSA, John Gibson, MBBS FRACP FRCPA DPhil, Douglas E. Joshua, MBBS DPhil FRACP FRCPA AM
Journal: Blood
Blood (2011) 118 (21): 4957.
https://doi.org/10.1182/blood.V118.21.4957.4957
Published: 2011
Journal Articles

Ten Year Survivors of Multiple Myeloma Demonstrate a Differential Expression of Immunological Biomarkers Including a High Incidence of Cytotoxic T-Cell Clones Which Have Not Acquired Myeloma-Associated Anergy,

Christian E Bryant, MBBS, Ross D Brown, DPhil, Shihong Yang, BSc, Hayley Suen, BSc, Esther Aklilu, BSc, James Favaloro, BSc, Derek NJ Hart, MBCHB, DPhil, Phillip Fromm, DPhil, Narelle Woodland, MSc, Najah Nassif, DPhil, Harry Iland, MBBS FRACP FRCPA MHGSA, John Gibson, MBBS FRACP FRCPA DPhil, P Joy Ho, MBBS, DPhil, Douglas E Joshua, MBBS, DPhil
Journal: Blood
Blood (2011) 118 (21): 3924.
https://doi.org/10.1182/blood.V118.21.3924.3924
Published: 2011
Journal Articles

HLA-G and CD86 Expression on Malignant Plasma Cells Convey a Poor Prognosis and Immunoregulate T Cells In Patients with Myeloma

Ross D. Brown, PhD, Karieshma Kabani, Shihong Yang, Esther Aklilu, Phoebe Joy Ho, MBBS, John Gibson, MBBS, Douglas E. Joshua, MBBS, DPhil
Journal: Blood
Blood (2010) 116 (21): 983.
https://doi.org/10.1182/blood.V116.21.983.983
Published: 2010
Journal Articles

Trogocytosis in Multiple Myeloma.

Ross D. Brown, PhD, MBA, Karieshma Kabani, BSc, Shihong Yang, MSc, Aklilu Esther, BSc, Phoebe Joy Ho, MBBS, DPhil, John Gibson, MBBS, PhD, Douglas E. Joshua, MBBS, DPhil
Journal: Blood
Blood (2008) 112 (11): 1681.
https://doi.org/10.1182/blood.V112.11.1681.1681
Published: 2008
Journal Articles

XBP-1 Levels Predict Sensitivity of Myelomas to Proteasome Inhibitor Bortezomib.

Silvia C. Ling, MBBS, FRACP, FRCPA, Edwin Lau, BSc, Lye L. Ho, MBBS, FRCPA, FRACP, Joy Ho, MBBS, FRCPA, FRACP, Douglas E. Joshua, MBBS, DPHil(Oxon)FR, John Allen, PhD
Journal: Blood
Blood (2007) 110 (11): 1473.
https://doi.org/10.1182/blood.V110.11.1473.1473
Published: 2007
Journal Articles

C-MYC Correlates with Expression of Multidrug Transporters ABCC1 and ABCC4.

Lye Lin Ho, MBBS, FRACP, FRCPA, Li Chong, PhD, Silvia Ling, MBBS, FRACP, FRCPA, Diana Lau, MSc, Edwin Lau, BSc, Harry Iland, MBBS, FRACP, FRCPA, Douglas E. Joshua, MBBS, DPhil, FRACP, John Allen, PhD
Journal: Blood
Blood (2007) 110 (11): 3467.
https://doi.org/10.1182/blood.V110.11.3467.3467
Published: 2007